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ABSTRACT OF THESIS

ANALYSIS OF POTENTIAL FACILITATORS TO USE OF HIV PRE-EXPOSURE
PROPHYLAXIS (PrEP) IN A YOUNG TRANSGENDER POPULATION
Pre-exposure prophylaxis for HIV prevention (PrEP) is heavily under-utilized in
transgender youth, a population which experiences high risk factors for contracting HIV
and exhibits unique barriers to care. This retrospective study used a secondary data analysis
of survey results from transgender youth between 16- and 24-years-old to analyze various
exposures for association with PrEP use. It was hypothesized that medical gender affirming
therapy, mental health care treatment, and HIV programming would be independently
associated with increased use of PrEP in transgender youth. It was found that only HIV
prevention services and programming related to HIV or gender identity were associated
with an increased use of PrEP. Results indicate that HIV- and transgender-focused services
outside of general primary care are the best way to improve PrEP access in this population.
KEYWORDS: Transgender Health, HIV Prevention, Pre-exposure prophylaxis, PrEP
access, Transgender HIV, Transgender youth
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CHAPTER 1. BACKGROUND
1.1

Introduction
HIV is a life-long condition that can take enormous costs to treat over a person’s

life. Prevention is the most important element of reducing the HIV burden, from a
population health, individual health, and cost-effectiveness standpoint. HIV prevention is
readily available in the form of safe-sex practices such as condoms, as well as medications
such as pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) for
individuals at higher risk of exposure. However, there are barriers that exist that prevent
at-risk individuals from knowing about and utilizing these options. PrEP is a uniquely
important preventative measure, as when used consistently it can proactively protect
individuals at the highest risk of transmission who for various reasons may not be able to
rely on barrier measures. The transgender population faces heightened risk for HIV, but
the prevention of HIV in this population has been studied less than in other notable highrisk populations, namely men who have sex with men (MSM) or injection drug users
(IDU). The transgender population already faces unique barriers in the healthcare system
due to stigma and a lack of education amongst healthcare providers on how to best
approach and care for this population. Therefore, it is important to understand what factors
affect access to HIV preventative care in this population so that this population can be
better reached in the future.

1.2

HIV in the Transgender Population
Despite not being thought of as an at-risk population for HIV as commonly as MSM

or IDU, transgender people do face an elevated risk of HIV. The nationally conducted
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NHBS Trans survey found that out of 1,608 transgender women, 42% were HIV positive
(Centers for Disease Control and Prevention, 2021b). A study of transgender youth (aged
16-24) found that 31% were HIV positive (Reisner et. al, 2017). These numbers are both
significantly higher than the estimated prevalence of HIV in the general United States
population, 0.3% (Centers for Disease Control and Prevention, 2021a).
The high prevalence of HIV in the transgender population can be explained by
several risk factors. Clinical trials of PrEP found that transgender women had more risk
factors for HIV than MSM, including more frequent transactional sex and higher average
number of sexual partners (Grant, et al., 2016). Transgender women have also been found
to be more likely to live at or below the poverty limit, be unemployed, and be homeless
than MSM (Wilson et. al, 2020). All of these socioeconomic factors can contribute to HIV
risk. Sex work is one consequence of poor socioeconomic status and workplace
discrimination for transgender people. A national survey found that 34% of transgender
women reported engaging in transactional sex (Centers for Disease Control and
Prevention, 2021b). This is especially troublesome as transgender sex workers have been
found to have an 8 times higher risk of developing HIV than cisgender sex workers
(Sherman et. al, 2019). Sex work, in addition to poor self-esteem, transphobia, and poor
health literacy, can contribute to other high-risk behaviors such as condomless anal sex.
Sex workers are more likely to engage in this risky sexual behavior in order to make a
living, and even more so when they experience gender discrimination and low self-esteem
as a result. A national survey of transgender women found that 52.8% of transgender
women reported having receptive condomless anal sex, which is one of the riskiest
behaviors for contracting HIV (Centers for Disease Control and Prevention, 2021b).
2

Transgender youth especially have been shown to have high rates of risk factors for
HIV development. Being assigned male at birth (AMAB) compared to being assigned
female at birth (AFAB), nonbinary gender identity, medical gender affirmation, and sex
work have all been identified as risk factors for STIs in transgender people aged 16-24
(Reisner et. al, 2019). A national survey of transgender youth found that over half of their
study population had been homeless (50.3%) or suffered from poverty (53.6%), and almost
half had participated in sex work (45.3%) (Jadwin-Cakmak et. al, 2019). A smaller study
demonstrated that transgender adolescents between the ages of 14 and 18 had largely
equivalent sexual practices to their cisgender peers (Number and gender of sexual partners,
age of first sexual encounter), except for higher rates of anal sex (Maheux et. al, 2021).
Despite having fairly similar sexual behaviors overall, lower socioeconomic status and
more frequent anal sex and transactional sex may put transgender adolescents at increased
risk for HIV.

1.3

HIV Care Continuum Integration
The HIV care continuum is an important concept that is relevant to all aspects of HIV

prevention and treatment. It is a model that includes all stages of HIV treatment from
diagnosis to maintained viral suppression. Introducing patients to the HIV care continuum
and keeping them involved with it is an important part of treating patients as well as
preventing them from spreading HIV to others. Establishing people in HIV care and
prevention is in itself a large hurdle, due to stigma, ignorance, and other socioeconomic
barriers such as cost and low health literacy. Transgender people are currently largely
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under-reached by HIV care and require increased efforts and a more tailored approach to
be integrated effectively.
Many barriers to HIV care have been identified for transgender people, including
socioeconomic issues, cultural issues, and issues related to experiences within the
healthcare system. These barriers include lack of care accessibility and security, providers'
misunderstanding of the transgender community, lack of cultural competency of
information systems and staff, HIV stigma, housing instability, substance abuse, mental
health issues, low health literacy, violence, medication side effects, and perceived conflicts
between transgender care and HIV care (Bocking et. al, 2020; Adams et. al, 2018; Hines
et. al, 2017). Participation in sex work can introduce additional barriers as sex workers
have a harder time keeping a consistent schedule with HIV care, and often must hide their
HIV status to protect their source of income. Race can compound the discrimination
experienced by transgender people in the healthcare system, which can become an
additional barrier to HIV care. Studies in San Francisco demonstrated that among
transgender women, the most likely participants to not be integrated in HIV care were those
who had experienced discrimination due to both their race and gender status (Baguso et.
al, 2019).
Culturally sensitive communication is greatly needed if transgender people are to
be better integrated into HIV care and prevention services. Interviews with transgender
women seeking care have revealed that stigma and discrimination are some of the most
important barriers to HIV care in this population (Hines et. al, 2017). Transgender people
in healthcare deal with being misgendered (referred to by pronouns that don’t align with
their gender identity), dead-named (called by the name they were formally known before
4

choosing a name that aligns with their gender identity), and harmful stereotypes or
assumptions made by healthcare staff. Importantly, transgender people have shown better
responses to staying in care when they feel systems and providers are affirming to their
gender identity (Sevelius et. al, 2019; Munro et. al, 2017). Further, it has been identified
that having an unmet need for medical gender affirmations, including hormones or
surgeries, is associated with poor HIV treatment retention (Rosen et. al, 2019; Baguso et.
al, 2019). On the other hand, it has been shown that transgender women who “pass” (are
publicly perceived as the gender they identify with, not the one they are assigned at birth)
may be less likely to bring up their gender identity, sexual risk factors, or HIV status and
concerns with healthcare providers because they don’t want to change how they are
perceived (Bocking et. al, 2020). Additionally, hormonal therapy for transitioning is
associated with higher rates of discrimination among transgender women, which may
contribute to lower retention in healthcare (Sha et. al, 2021). These findings indicate the
need for healthcare providers to be able to treat transgender people as their preferred gender
while still being able to appropriately find ways to discuss HIV risk factors. This is
supported by recommendations that have been made for systems-level changes to
healthcare systems, including education for all staff members, improved gender identity
information recording in electronic health records, and more inclusive approaches to taking
sexual histories (Deutsch, 2018).
Reducing the complexity of navigating the healthcare system is another way that
has been shown to improve the involvement of transgender people in the HIV care
continuum. Several studies have found evidence that having a care facilitator refer at-risk
individuals from primary care to HIV treatment and prevention centers and set up
5

appointments for patients is one of the most effective facilitators for integrating transgender
people into care (Hines et. al, 2017; Munro et. al, 2017; Rocha et. al, 2020). Approaches
that reduce the difficulty of being seen by healthcare providers and that are specifically
tailored to transgender care and/or HIV have shown increased retention of care, including
PrEP-only clinics and a text-based service for transgender women in HIV care (Wilson et.
al, 2021; Reback et. al, 2021). These approaches and other methods for improving
transitions of care represent valuable opportunities for keeping transgender people in the
HIV care continuum.

1.4

PrEP Use in the Transgender Population
An even bigger hurdle for HIV care in transgender people than treatment retention

is prevention. Specifically, PrEP is heavily under-utilized as a preventative measure.
Compared to MSM, transgender women are less likely to know of PrEP, discuss it with a
healthcare provider, or take it (Wilson et. al, 2020). A recent national survey has found
that while 90% of HIV-positive transgender women were currently taking antiretrovirals
for treatment, only 32% of HIV-negative transgender women had used PrEP at any point
in the past twelve months (Centers for Disease Control and Prevention, 2021b). While not
all these HIV-negative women would have been indicated for PrEP, evidence shows that
there is a large discrepancy in the number of transgender women who are indicated for
PrEP and the number who utilize it. One study found that out of 180 transgender women
aged 18-29, 62% were indicated for PrEP but only 5% had taken PrEP at any point (Kuhns
et. al, 2016). There is even less data on PrEP in transgender men compared to transgender
women, but it appears that there is still underutilization of PrEP in this population. One
6

survey of 843 transgender MSM living without HIV found that while 55.2% were
indicated for PrEP, only 28.0% utilized PrEP (Reisner et. al, 2021). Even though there
have not been trials of PrEP efficacy and safety specifically in transgender people, trials
of PrEP medications have included a substantial and diverse number of transgender
women (Grant et. al, 2016). Due to this, PrEP should be considered a safe and effective
medication in all transgender people at high risk for HIV. In fact, according to some
recommendations, any transgender person who asks a medical provider about PrEP is
indicated for PrEP, as they may have risk factors that they are not willing to share with
their providers due to perceived stigma (Deutsch, 2018).
Appropriate utilization of PrEP requires high awareness, high acceptability, and for
barriers to access to be removed or minimized. Studies in transgender women have found
that acceptability of PrEP tends to be high, but that awareness of PrEP tends to be low
(Pacífico de Carvalho et. al, 2019). Lack of PrEP awareness can be attributed to the
healthcare system’s poor approach to transgender inclusivity as well as a lack of studies of
and marketing for PrEP in this population (Sevelius et. al, 2016). In the last couple years,
research and marketing for PrEP has improved, as can be evidenced by transgender
individuals now being included in commercials for Truvada, but there may still be a deficit
here. Several facilitators have been identified with PrEP awareness among transgender
people and may give insight into how PrEP utilization can be improved in this population.
Medical gender affirmation has been shown to be associated with greater PrEP awareness
in transgender male and nonbinary youth (Andrzejewski et. al, 2021). In transgender
people who do use PrEP, research participation was often the key to initiation of
therapy. A study in Brazil from 2019 found that out of a sample of 322 transgender
7

women, the only ones who utilized PrEP had received it from participating in another
research program, despite high risk factors throughout the sample (Ferreira et. al,
2019). Facilitators to PrEP uptake in transgender men have been shown to be similar to
those found in transgender women: surgical gender affirmation, no experiences of
discrimination in healthcare, and receiving health information from social media (Reisner
et. al, 2021). When transgender women were consulted with on how best to improve HIV
prevention access, the consensus was that an integrated approach to care and reduced
stigma in the healthcare system were necessary to improve PrEP accessibility (Sevelius et.
al, 2019). This is supported by results that demonstrated that transgender people at highrisk for HIV were more likely to use PrEP-only clinics compared to general primary care
clinics (Wilson et. al, 2021).
Barriers that have been identified to PrEP use include cost, poor adherence, side
effects, perceived potential interactions with hormone therapy, stigma, lack of transgender
women in PrEP advertising, and poor experiences with healthcare workers (Pacífico de
Carvalho et. al, 2019; Rael et. al, 2018; Watson et. al, 2020). Race may also be a barrier to
PrEP uptake due to systemic discrimination in the healthcare system: one Florida study
revealed that among 60 transgender women, African American women were the least
likely to be aware of PrEP, and none of the African American women surveyed were using
PrEP (Holder et. al, 2019). This was despite the African American transgender women in
their sample having the highest number of risk factors for HIV, including multiple sexual
partners, sex work participation, and condomless anal sex (Holder et. al, 2019).
Transgender youth face additional barriers, often due to living with their parents with
whom they do not wish to disclose their gender identity and/or HIV risk factors. A survey
8

of 15–24-year-old transgender youth identified that the need for frequent healthcare visits
was a large barrier to PrEP in this age group, as it made privacy from parents more difficult
(Horvath et. al, 2019). These youth were more likely to find PrEP acceptable if acquired
through research programs or if they could receive PrEP as a long-acting injectable
(Horvath et. al, 2019).
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CHAPTER 2. SPECIFIC AIMS
2.1

Specific Aims & Hypotheses
Because the transgender population is at an elevated risk for HIV prevention, the

underutilization of HIV preventative medications such as PrEP is a critical issue to be
solved. Younger transgender individuals may face an even higher risk for contracting HIV,
and less is known about ways to minimize barriers to and facilitate PrEP uptake in this
subpopulation. This study aimed to analyze the proportion of transgender individuals aged
16-24 who utilized PrEP based on important facilitating factors.
The specific aims are as follows:
1. Evaluate whether the utilization of gender affirming medical therapy is
associated with the use of HIV pre-exposure prophylaxis in transgender people
aged 16-24.
It was hypothesized that transgender people aged 16-24 who received gender
affirming medical therapy would be more likely to utilize HIV pre-exposure
prophylaxis.
2. Evaluate whether the utilization of mental health care is associated with the
use of HIV pre-exposure prophylaxis in transgender people aged 16-24.
It was hypothesized that transgender people aged 16-24 who were seen by
mental health professionals would be more likely to utilize HIV pre-exposure
prophylaxis.
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3. Evaluate whether involvement in HIV- or transgender-focused programs or
research studies is associated with the use of HIV pre-exposure prophylaxis in
transgender people aged 16-24.
It was hypothesized that transgender people aged 16-24 who were involved with
programs or research studies focused on HIV or transgender health would be
more likely to utilize HIV pre-exposure prophylaxis.
The rationale for the first hypothesis was that the lack of gender affirming medical therapy
is a barrier to receiving HIV preventative care, as transgender youth may feel less
comfortable in healthcare settings when they are not able to present themselves as the
gender with which they identify. The rationale for the second hypothesis was that improved
mental health could allow transgender youth to focus more on other aspects of their health
including HIV prevention, and potentially avoid risky sexual behaviors such as condomless
anal sex that have been associated with low self-esteem. The rationale for the third
hypothesis was that programs focused specifically on either HIV or transgender health
would be successful in improving PrEP uptake, as they remove many of the barriers to
PrEP found in general primary care settings, such as discrimination or lack of education of
providers on transgender patients.

2.2

Significance
As the transgender population faces high rates of HIV transmission and unique

barriers to integration within the healthcare system, this study will provide additional
insight into what barriers and facilitators to accessing HIV PrEP exist in this population.
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By understanding these barriers and facilitators, we can learn to improve the ability of the
healthcare system to reach at-risk transgender individuals who would benefit from HIV
prevention, and thereby reduce HIV transmission, morbidity and mortality, and overall cost
to the healthcare system.

2.3

Approach
A randomized control trial to evaluate the effects of gender affirming medical

therapy and mental health services on PrEP uptake in transgender youth would require
transgender youth to be randomized to not receiving potentially important medical
services. For this reason, it would be unethical to conduct a randomized trial, and an
observational study must be used. An ideal study design would be a widely distributed
survey tool with questions specifically designed for the objectives of this study. This
approach would necessitate a significant amount of time to develop an effective and
culturally sensitive survey tool and then distribute it to a large enough population. This
time would be even greater considering this is a hard-to-reach population that is often
mistrusting of medical professionals. No large-scale survey studies have been performed
yet in transgender youth that are focused on PrEP uptake. Studies that have focused on
barriers to PrEP have mostly focused on adult transgender people, largely only included
transgender women, and only focused on self-reported barriers rather than finding
associations with actual PrEP use. This study instead utilizes a secondary analysis of a
known dataset from a survey that has already been conducted in transgender youth at risk
for HIV. This approach allows for a relatively large sample size to be used to analyze reallife data on what factors are associated with PrEP uptake in this population. Limitations of
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this approach include inability to control for certain confounders, and inability to define
exposures and outcome variables as would be most appropriate for this study’s objectives.

CHAPTER 3. METHODOLOGY
3.1

Overall Approach
This retrospective observational study utilized a secondary analysis of quantitative

survey results to explore possible predictors of access to HIV pre-exposure prophylaxis in
a young, transgender population. De-identified survey data was accessed under a data use
agreement with the original NIH investigators through the NIH Data and Specimen Hub
(DASH). Data analysis was performed using R version 3.6.1 software.

3.2

Data Source
The data source used for this study was the Adolescent Medicine Trials Network for

HIV/AIDS Interventions (ATN) 130 study dataset. ATN 130 was titled “Assessing the
Engagement of Transgender and Other Gender Minority Youth Across the HIV Continuum
of Care”. ATN 130 was a mixed-methods study that collected both quantitative surveys
and qualitative interviews from study participants (Jadwin-Cakmak et. al, 2019). The
purpose of ATN 130 was to gather data on the experience of this population with HIV
preventative services, and its similarity to the objectives of this study means that it
contained many useful data elements that could be correlated with PrEP use. While ATN
130 assessed subjects for a history of using PrEP, PrEP-use was not a primary outcome
analyzed for association with barriers and facilitators in ATN 130. The dataset contains
participants who were transgender and other gender minority youth aged 16-24-years-old.
13

“Other gender minority youth” included individuals who had a nonbinary gender identity,
i.e., they identified as a gender not strictly male or female. The surveys distributed to these
participants contained questions about various experiences related to the HIV care
continuum, as well as general demographic information. The surveys were carefully
constructed to be clearly understandable to people of any level of health literacy, and
culturally sensitive to transgender youth so as to not make subjects uncomfortable or
offended. Surveys were distributed to transgender and other gender minority youth who
presented at Adolescent Medicine Trials Unit (AMTU) sites located in one of fourteen
cities (Baltimore, Boston, Chicago, Denver, Detroit, Houston, Los Angeles, Memphis,
Miami, New Orleans, New York City, Philadelphia, Tampa, and Washington D.C.) located
throughout the United States. AMTU sites are locations within the Adolescent Medicine
Trials Network dedicated to preventing and treating HIV in youth. Surveys could be
distributed by medical providers, mental health professionals, case manager/care
coordinators, HIV test counselors, or health educator/outreach workers who had a history
of working with this population. Surveys were collected from July 15, 2015, to January 15,
2016. No exclusion criteria were used for choosing this survey population.

3.3

Inclusion & Exclusion Criteria
Subjects were excluded from analysis who were HIV-positive at the time they

completed the survey, as these individuals would have no reason to utilize HIV prevention
such as PrEP. Individuals who had tested negative or were unaware of their HIV status
due to a lack of testing history were included, as they could potentially be indicated for
PrEP. While having a negative HIV test is required before initiating PrEP, individuals who
had no history of being tested for HIV were considered negative and could have been
14

referred for HIV testing if PrEP was otherwise indicated. Individuals were also excluded
who did not respond to the survey question related to history of PrEP use. In order to
maintain a widely representative sample and avoid reducing power of the study, no other
exclusion criteria were used. Subjects of any gender minority group were included,
including transgender females, transgender males, non-binary, gender neutral, and demigender individuals. The final study sample contained n=123 transgender individuals aged
16-24 who were either HIV-negative or unaware of their HIV status, after excluding the
59 HIV-positive individuals and 4 individuals with unknown PrEP history from the 186
total subjects contained within the ATN 130 dataset.
Figure 3.1 Flow Chart of Sample Selection
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3.4

Exposures
Several exposures were identified based on the survey questions included in the

dataset that could be used to answer the study hypotheses. In order to determine whether
mental health service access was associated with higher uptake, the exposure used for
analysis was whether or not the subject had a visit with a healthcare professional in the past
12 months. Exposures related to gender affirming therapy included a primary exposure of
whether or not medical gender affirming therapies (including hormones, pubertal blockers,
or any surgery related to gender expression) had ever been used, and secondary exposure
variables of use of hormones for gender affirming therapy, social gender affirmation (living
full-time in their preferred gender identity), legal gender affirmation (changing name and
gender on official documentation), experience with HIV preventative services being
focused towards transgender individuals, having a healthcare provider knowledgeable
about transgender health, and having a family supportive of gender identity. Another
exposure, history of avoiding healthcare due to gender identity, was included as a negative
factor related to gender affirmation, to see if it affected PrEP use negatively. These
secondary exposures were picked as they were related to a positive history of gender
affirmation. Other primary exposures included were a history of involvement with any HIV
prevention service (including risk reduction counseling, demonstrations on how to properly
use condoms, programs for couples or groups focused on reducing the risk of acquiring
HIV by changed behavior), or participation in any program (including research studies,
support groups, or counseling sessions) related to HIV, sexual risk, relationships, gender
identity or expression, or sexuality. Exposures were defined based on responses of
participants to ATN 130 survey questions as defined in Appendix A.
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3.5

Outcomes
The primary outcome of this study was PrEP use. PrEP use was defined as a binary

variable based on the response of participants to the survey item: “Have you ever taken
HIV medication before sex because you thought it would lower your chances of getting
HIV (also known as PrEP)?”. Based on this, the outcome of PrEP use included all
individuals who had ever used PrEP. Timing of PrEP initiation or duration of PrEP therapy
could not be determined from the dataset.

3.6

Confounding
Potential identifiers were identified based on factors that had been identified in the

literature that may affect PrEP uptake as well as any of the primary exposures. These
included demographics such as age, gender identity (transgender female, transgender
male, and nonbinary) and being assigned male at birth (AMAB), race, and education.
Socioeconomic factors included foster care, homelessness, poverty (history of receiving
governmental assistance programs was used as a measure), and incarceration. Factors
related to mental health included depression, anxiety, self-esteem, suicidal ideation,
suicide attempts, and physical or sexual abuse ever or before the age of 15. Sexual risk
factors were also included a history of sex work, injection drug use, STI screening, STIs,
sexual history based on sexual partners in the past 6 months, and sexual history of anal
sex, condomless sex, and anal condomless sex. A directed acyclic graph was constructed
to illustrate the proposed relationships between these confounders and the exposure and
outcome variables and can be seen in Figure 3.2. Potential confounders were assessed for
statistically significant differences between the two outcome groups and included in
Table 1. Detailed definitions of demographics and confounders available in Appendix 2.
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Figure 3.2 Directed Acyclic Graph

3.7

Statistical Analysis
Statistical analysis was performed using R version 3.6.1. Summary statistics were

used to describe the sample. Categorical variables were described with percentages, and
frequencies were described with mean ± standard deviations. Primary analyses were
bivariate utilizing chi-square and Fisher exact tests for categorical variables, and two-tailed
t-tests for continuous variables. For categorical variables, chi-square tests were used except
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where any expected counts were less than 5, in which case Fisher exact tests were used.
All tests were performed with 95% confidence intervals.
Two secondary analyses were conducted to eliminate potential confounding. These
confounder analyses were selected based on confounders expected to have the greatest
effect on PrEP use and the exposures of the study. The first included only assigned male
at birth (AMAB) subjects, as these subjects may be more likely to be indicated for PrEP
due to sexual risk behaviors. The other secondary analysis that was conducted excluded
all uninsured patients, as they would be less likely to be able to afford PrEP or use other
mental health services or gender affirming medical therapy.

CHAPTER 4. RESULTS
4.1

Overall Sample Description
The study sample consisted of 123 subjects, of whom 112 had never used PrEP and

11 had used PrEP. The baseline characteristics of PrEP users and non-PrEP users are
described in Table 4.1. The average age of the sample was 20.5 ± 2.35 years. The overall
study population was fairly diverse within the category of transgender youth aged 16 to
24. While many studies on PrEP in transgender people focus on transgender women, this
study included 55.3% transgender women, 23.6% transgender men, and 21.1% nonbinary
individuals. 65.6% of the study population were AMAB. The study sample was 30.1%
Hispanic or Latino, 28.5% white, 56.9% black, 4.1% Native American or Alaska natives,
1.6% Asian or Pacific Islander, and 8.9% mixed or another race. PrEP users were more
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likely to be transgender female (p=0.02) and AMAB (p=0.01). In all other aspects PrEP
users and non-users were similar.

Table 4.1 Demographic Characteristics and Presence of Potential Confounders in Study Sample
Total Sample
No PrEP Use
PrEP Use
Test
P(n=123)
(N=112)
(n=11)
Statistic value
Age

20.50

2.35 20.46

2.31 21.00

2.76

-0.54 0.4652

10 90.91%

9.19 0.0221

Gender Identity
Transgender Female

68 55.28%

58 51.79%

Transgender Male

29 23.58%

29 25.89%

0

0.00%

0.00 0.0652

Non-binary

26 21.14%

25 22.32%

1

9.09%

0.35 0.4548

AMAB

80 65.57%

69 62.16%

11 100.00

∞ 0.0152

37 30.08%

34 30.36%

3 27.27%

0.86

1

White

35 28.46%

32 28.57%

3 27.27%

0.94

1

African American or Black
Native American or Alaska
Native

70 56.91%

62 55.36%

8 72.73%

2.14 0.3478

Ethnicity
Hispanic/Latino
Race

5

4.07%

5

4.46%

0

0.00%

0.00

1

2

1.63%

2

1.79%

0

0.00%

0.00

1

Other

11

8.94%

11

9.82%

0

0.00%

0.00 0.596

Education
Less than High School
Diploma
High School Diploma or
GED

41 33.33%

39 34.82%

2 18.18%

0.42 0.3334

45 36.59%

39 34.82%

6 54.55%

2.23 0.2079

College

37 30.08%

34 30.36%

3 27.27%

0.86

Depression

71 57.72%

67 59.82%

4 36.36%

0.39 0.2003

Anxiety

74 60.16%

70 62.50%

4 36.36%

0.35 0.1127

High Self-Esteem

92 74.80%

83 75.45%

9 81.82%

1.46

Suicidal Ideation

75 60.98%

69 61.61%

6 54.55%

0.75 0.7494

Attempted Suicide
Physical or Sexual Abuse
Ever

50 40.65%

48 42.86%

2 18.18%

0.30 0.1966

47 40.52%

42 39.62%

5 50.00%

1.52 0.5234

Asian or Pacific Islander

1

Mental Health
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Table 4.1 Demographic Characteristics and Presence of Potential Confounders in Study Sample
Physical or Sexual Abuse
Under Age of 15
58 50.88%
53 51.46%
5 45.45%
0.14 0.7051
Socioeconomic
Health Insurance
Cost Prevented Healthcare
Access in Past 6 Months

105 85.37%

96 85.71%

9 81.82%

0.75 0.6631

29 23.58%

27 24.11%

2 18.18%

0.70

1

Regular Healthcare Site

96 84.21%

86 83.50%

10 90.91%

1.97*

1

Foster Care

22 19.30%

21 20.39%

1

9.09%

0.39 0.6881

Homelessness

60 49.18%

54 48.65%

6 54.55%

0.14* 0.709

Government Assistance

62 55.86%

58 58.00%

4 36.36%

0.42 0.2093

Incarceration

42 34.43%

38 34.23%

4 36.36%

1.10

48 39.02%

43 38.39%

5 45.45%

1.33 0.7494

3.67%

1 10.00%

2.88 0.3603

1

HIV Risk Factors
Sex Work
Injection Drug Use

5

4.20%

4

STI Screening History

79 64.75%

71 63.96%

8 72.73%

1.50 0.7451

STI History
Sex with Male in Past 6
Months
Sex with Female in Past 6
Months
Sex with Transgender in
Past 6 Months

26 21.31%

23 20.72%

3 27.27%

1.43 0.6997

71 58.20%

63 56.76%

8 72.73%

2.02 0.3563

26 21.31%

26 23.42%

0

0.00%

0.00 0.1181

25 20.49%

22 19.82%

3 27.27%

1.51 0.6945

Anal Sex in Past 6 Months

47 38.21%

41 36.61%

6 54.55%

2.07 0.331

74 60.16%

67 59.82%

7 63.64%

1.17

31 25.20%

27 24.11%

4 36.36%

1.79 0.4664

Condomless Sex in Past 6
Months
Condomless Anal Sex in
Past 6 Months
Frequency of Anal Sex in
Past 6 Months
Frequency of Condomless
Sex in Past 6 Months
Frequency of Condomless
Anal Sex in Past 6 Months

9.77
18.83
2.84

31.47

1

8.92

28.65 18.45

53.68

-9.53 0.3397

42.33 18.61

42.32 21.09

44.53

-2.48 0.8536

12.08

10.29

23.98

-5.37 0.1603

2.36

7.73

*Test statistic is a chi-square. All other categorical variables use Fisher’s exact test due to
an expected cell count <5.
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4.2

Primary Analysis
Prevalence of exposure variables across PrEP users and non-users in the total study

sample is described in Table 4.2. No exposures related to mental health care or gender
affirmation were found to be significantly associated with PrEP use. Participation in any
HIV prevention services was associated with higher PrEP use, with 90.9% of PrEP users
having program participation compared to only 50.45% of PrEP non-users (p=0.01).
Program participation was also strongly associated with PrEP use, with 90.91% of PrEP
users claiming participation and only 39.09% of PrEP non-users claiming participation
(p=0.01).
Table 4.2 Exposures in PrEP Users and Non-Users
No PrEP Use PrEP Use Test
(n=112)
(n=11) Statistic

P-value

Seen by Mental Health Professional

62

55.36%

7 63.64% 1.41

0.754

Medical Gender Affirming Therapy

67

59.82%

7 63.64% 1.17

1

Hormones for Gender Affirmation

66

58.93%

7 63.64% 1.22

1

Living Full-Time in Preferred Gender Identity

86

76.79%

8 72.73% 0.81 0.7198

Legally Affirmed Gender

23

21.90%

3 27.27% 1.33

Transgender-Focused HIV Prevention Experience 33
Provider Knowledgeable About Transgender
Health
77

57.89%

4 40.00% 0.49 0.3241

Family Supportive of Gender Identity

69

65.71%

9 81.82% 2.33 0.3363

Gender Identity Prevented Healthcare Access
in Past 6 Months

25

22.32%

0

HIV Prevention Service Participation

56

50.45%

10 90.91% 6.60* 0.01021

Program Participation

43

39.09%

10 90.91% 15.29 0.00109

70.64%

10 90.91% 4.12

0.00% 0.00

0.708

0.286

0.118

*Test statistic is a chi-square. All other categorical variables use Fisher’s exact test due to
an expected cell count <5.
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4.3

Secondary Analyses
Secondary analyses supported the results of the primary analyses. Table 4.3

describes the differences in exposures between PrEP users and non-users when only
AMAB participants were included. This analysis contained 80 AMAB participants
compared to the 123 total study participants. The same two variables were the only
exposures found to be associated with PrEP use. The proportions of PrEP users and nonusers who claimed these two exposures were nearly identical in this confounder analysis
as in the primary analysis containing the total sample. All PrEP users from the total study
sample were AMAB.

Table 4.3 Exposures in PrEP Users and Non-Users Among AMAB Subjects
No PrEP Use
PrEP Use
Test
(n=69)
(n=11)
Statistic

Pvalue

Seen by Mental Health Professional

33

47.14%

7

63.64%

1.03 0.3091

Medical Gender Affirming Therapy

39

55.71%

7

63.64%

1.39 0.7492

Hormones for Gender Affirmation
Living Full-Time in Preferred Gender
Identity

37

52.86%

7

63.64%

1.55 0.7462

57

81.43%

8

72.73%

0.61 0.4474

Legally Affirmed Gender
Transgender-Focused HIV Prevention
Experience
Provider Knowledgeable About
Transgender Health

11

15.71%

3

27.27%

1.99 0.3927

27

65.85%

4

40.00%

0.35 0.1627

53

77.94% 10

90.91%

2.80 0.4457

Family Supportive of Gender Identity

42

61.76%

9

81.82%

2.75

Gender Identity Prevented Healthcare
Access in Past 6 Months

10

14.29%

0

0.00%

0.00 0.3427

HIV Prevention Service Participation

40

57.97% 10

90.91%

7.12 0.0457

Program Participation

27

39.13% 10

90.91%

10.23* 0.0013

0.311

*Test statistic is a chi-square. All other categorical variables use Fisher’s exact test due to
an expected cell count <5.
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The second confounder analysis which included only participants with health insurance
also found the same two exposures to be associated with PrEP use. Proportions of PrEP
users and non-users in the insured population were similar with the proportions in the total
population. Nine of the eleven PrEP users from the study population had health insurance.

Table 4.4 Exposures in PrEP Users and Non-Users Among Insured Subjects
No PrEP Use
PrEP Use
Test
(n=96)
(n=9)
Statistic P-value
Seen by Mental Health Professional

57

59.38% 7

77.78%

2.38

0.477

Medical Gender Affirming Therapy

61

63.54% 7

77.78%

2.00 0.4879

Hormones for Gender Affirmation
Living Full-Time in Preferred Gender
Identity

59

61.46% 7

77.78%

2.18 0.4791

73

77.66% 6

66.67%

0.58 0.4317

Legally Affirmed Gender
Transgender-Focused HIV Prevention
Experience
Provider Knowledgeable About
Transgender Health

21

22.11% 3

33.33%

1.75 0.4277

27

56.25% 3

37.50%

0.47 0.4507

67

71.28% 8

88.89%

3.20 0.4382

Family Supportive of Gender Identity
Gender Identity Prevented Healthcare
Access in Past 6 Months

61

64.89% 7

77.78%

1.88 0.7146

22

22.92% 0

0.00%

0.00 0.1986

HIV Prevention Service Participation

47

49.47%

88.89%

8.04 0.0338

Program Participation

37

38.95%

88.89%

14.39 0.00243

CHAPTER 5. DISCUSSION & CONCLUSION
5.1

Discussion
The study population was shown to have high risk factors for HIV, despite low

PrEP use. Over a quarter of the study population (25.2%) participated in condomless anal
sex, and over half (60.2%) participated in condomless sex in the past six months at the
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time of survey. Over a third of the population had participated in transactional sex (39.0%).
Despite this high risk, only 8.9% of the study population used PrEP. This demonstrates
that PrEP is being highly under-utilized in young transgender individuals. PrEP users and
non-users were highly similar in terms of demographics and potential confounders. The
only significant differences in PrEP users and non-users were gender identity and assigned
gender at birth. PrEP users were almost entirely transgender women (90.1%) and entirely
AMAB. Transgender women are often thought of as having more risk factors than
transgender men, partially due to higher rates of anal sex. This difference does not appear
to impact upon the results of this study, however, as the same significant associations were
found when only AMAB individuals were included in the study (Table 4.3). The other
confounder analysis, excluding those without health insurance, also revealed no
differences from the primary analysis (Table 4.4).
HIV preventative services and program participation (related to HIV, sexual risk,
relationships, gender identity or expression, or sexuality) were found to be associated with
PrEP use. 90.9% of PrEP users had utilized HIV prevention services compared to only
50.5% of non-users (p=0.01). While many transgender youths who participated in HIV
preventative services such as risk reduction counseling or condom demonstrations did use
PrEP, almost all transgender youth who used PrEP had participated in one of these
services. These HIV preventative services seem to be an important facilitator to PrEP use.
HIV preventative services, which as defined by this study included many simple and nontime-consuming services, seem to be associated with greater PrEP use. General HIV
preventative education programs, risk reduction counseling, and condom information
sessions may be a great and cost-effective way to improve PrEP use and reduce HIV in
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transgender youth. The other exposure found to be associated with PrEP use, program
participation, showed an even greater association. "Program participation” here includes
interventions, research studies, support groups or individual counseling sessions about
HIV, sexual risk, relationships, gender identity, gender expression, or sexuality. While
90.9% of PrEP users participated in one of these programs, only 39.1% of PrEP non-users
had participated (p=0.01). What this seems to indicate is that larger interventions focused
on HIV, transgender health, or other topics related to sexuality and gender seem to be the
greatest facilitator to PrEP use. Previous studies had indicated that research programs
which distributed PrEP directly to participants were one of the most acceptable forms of
acquiring PrEP for transgender youth. Another common finding is that transgenderfocused programs are much more effective for HIV prevention and treatment with
transgender people. The results of this study seem to confirm those findings. From the
results of this study, it would appear that transgender youth who only see routine primary
care (84.2% of this study population had a regular site to receive healthcare) and do not
additionally access some form of HIV- or transgender health-focused program or service
are very unlikely to receive PrEP, even if their risk factors for HIV are high. As
confounding was not entirely controlled for in this study, there could be some bias in that
transgender youths who were more at-risk for HIV were both more likely to participate in
these programs and also be more likely to use PrEP. However, it is worth keeping in mind
that risk factors for HIV such as condomless sex use and sex work were similar between
PrEP users and non-users in the study population.
The results of this study did not support the other hypotheses. Neither being seen
by a mental health professional nor gender affirming medical therapy were found to be
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associated with PrEP use. There are several factors that may influence this. The study may
have simply been underpowered to reveal an association, or confounding may not have
been sufficiently controlled for. One explanation for why gender affirming therapy did not
reveal an association with PrEP use could be that gender affirmation can be both a
facilitator and barrier to HIV prevention and PrEP use. While gender affirmation may
make transgender youths feel more comfortable and therefore more willing to seek care,
they may also fear stigmatization by healthcare professionals to a greater extent (Sevelius
et. al, 2019; Munro et. al, 2017; Bocking et. al, 2020; Sha et al., 2021). Further, transgender
youth who are identified as their preferred gender identity by healthcare providers may
enjoy this feeling, and not want to risk being stigmatized by bringing up HIV risk factors.
Another issue is that the definition of mental health treatment as an exposure may have not
been appropriate. Mental health treatment was defined by whether or not an individual had
participated in at least one discussion with a mental health provider in the past 12 months.
This indicator tells little about the overall mental health treatment of the participant. It
would have been more illuminating if the mental health care could have been further
broken down by type of provider and number of appointments.
There are some important characteristics of this study population that should be
kept in mind when considering these results. One is related to the age of this population,
16-24. Age did not seem to play an effect in PrEP use based on the results of this study, as
PrEP users and non-users were essentially the same age (average age of PrEP users=21.0,
average age of non-users=20.5). However, at this age, many if not all of the participants
are likely still on their parent’s health insurance plan, and/or living with their parents.
These could be factors that make youth feel less comfortable accessing HIV prevention
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services or PrEP if they are worried about having potential conversations with their parents
about HIV risk. However, for this study population it is worth noting that family support
tends to be relatively high, with 67.2% of the sample saying that they feel their family is
supportive of their gender identity. This is likely higher family support than can be
expected in the general population. It is worth noting that for this high family support, as
well as the high access to a regular healthcare site, and the fact that all of this sample had
been in contact with an AMTU site or professional (including physicians, counselors, and
case workers) indicates that this sample may have had many factors that made it easier for
this population to access PrEP. A bias inherent to the selection of this sample through
AMTU sites, such as community centers or healthcare clinics, means that everyone in this
sample was seen at least once by some sort of professional that could offer help with
transgender or HIV issues. This would indicate that this study population may be more
likely to get PrEP if needed than other transgender youth. This makes the severe
underutilization of PrEP seen in this sample even more stark.
Due to the exploratory nature of this study and its low power, it may be worth
briefly discussing some of the non-statistically significant results. While the differences
were not enough to reach statistical significance in this population, PrEP users were more
likely to report having a healthcare provider who was knowledgeable about transgender
health (90.9% to 70.6% in non-users) and to report having a family supportive of their
transgender identity (81.8% to 65.7% in non-users). PrEP users also reported zero instances
in which they avoided healthcare due to their gender identity, while 22.3% of non-users
reported having done this in the past six months. These factors may play a role and could
be explored in future studies with larger power.
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This study has several important limitations to keep in mind. First, the study is
likely underpowered due to the sample size (n=123). It is possible that a larger sample size
would have revealed additional factors to be associated with PrEP use. Additionally, the
nature of the dataset itself implies limitations inherent to survey results and secondary
analyses. Not all factors could be controlled for appropriately if the original survey tool
did not collect information on them or if they were defined differently than what would be
most appropriate for this study. The timing of exposures and outcomes could only be
understood as they were defined by the survey tool. For example, the outcome, PrEP use,
was defined as the use of PrEP at any time in history, whereas the outcomes were defined
as either having occurred in the last 12 months or at any time in history. Due to this, it is
possible that the “exposures” occurred or began after the “outcomes”, which distorts the
view of the relationship being studied. It would be more appropriate if information was
available on when PrEP was started in relation to exposures such as mental health
treatment or medical gender affirmation. The analysis also relies on the subjective
responses of study participants, which are subject to misremembering, misunderstanding,
or subjects choosing not to respond to certain questions that made them feel
uncomfortable. In a few of the bivariate analyses conducted, the total sample was smaller
than n=123 due to missing responses from one or more subjects. Overall, the responses to
the survey tool are believed to be largely reliable, however, due to the survey being
completely anonymous, allowing subjects to only answer questions they feel comfortable
answering, and all portions of the survey being phrased in a culturally sensitive and wellexplained manner as to not be confusing. The population of this study is also a limitation
to how its results can be extrapolated. While the sample for this study was diverse in terms
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of gender identity, race, ethnicity, and geographical region within the United States, it only
contains subjects from a limited age range and subjects from urban environments. Due to
these restrictions, the results from this study cannot be used to make any statements about
transgender people over the age of 24 or who live in rural or suburban communities.
Another limitation is that due to the nature of this being an observational study, potential
confounders could not be fully controlled. Additionally, not all potential confounders
identified could be determined using the survey tool generated. This study did not utilize
propensity scoring in order to control for the confounders identified. Another important
limitation is that it was not possible to accurately determine PrEP indication for each study
participant due to the nature of the dataset. If this could have been determined, the study
could have excluded all participants who were not indicated for PrEP and the analysis
could have focused only on appropriate PrEP use rather than total PrEP use. This outcome
would have been more beneficial in revealing how to improve effective HIV prevention.
Finally, a limitation is that PEP was not able to be included in the analysis due to no
questions on PEP in the ATN 130 survey. While PEP is utilized much less than PrEP for
HIV prevention, it does factor into medical HIV prevention and not assessing its use may
skew results.
Future studies on barriers and facilitators to PrEP in transgender people could
expand upon this study in several ways. It would be interesting to analyze the differences
in PrEP association with various types of HIV preventative services and programs to
determine if any had a greater significance. While the results of this study indicated that
HIV prevention services as a whole and program participation as a whole both were
associated with greater PrEP use, future studies could break down the association across
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various types of services and programs in order to determine what approaches are the most
effective at increasing PrEP uptake. Future studies could also increase the study size and
potentially include a wider age range of transgender people. A survey designed specifically
around PrEP use could be particularly helpful in defining variables for analysis more
appropriately.

5.2

Conclusion
The results of this study indicate that the best predictors of PrEP use in transgender

youth are participation in HIV preventative services and programs, including research
studies, focused on HIV, gender identity, or sexuality-related topics. This is indicative that
the main ways this population are currently being reached for HIV prevention are HIV- or
transgender-focused prevention programs or services, including research studies. This is
important as transgender youth may be unlikely to use PrEP when needed if they are only
seen at routine primary care. The need for transgender- and HIV-focused preventative
efforts is highlighted. More needs to be known about what types of these preventative
services and programs are the most effective at improving appropriate PrEP use.
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APPENDICES
APPENDIX 1. Coding of Exposures from ATN 130 Dataset
Exposure

Survey Question

Positive
Response(s)

Seen by Mental
Health Professional

“Now I would like to ask you if, in the past 12
months, you have seen a psychiatrist, psychologist,
marriage & family therapist, or social worker about
the way you were feeling or behaving?”

Yes

Medical Gender
Affirming Therapy

“Have you accessed any medical interventions to
affirm your gender (for example, hormones,
surgeries to transition)?”

Yes

Hormones for Gender
Affirmation

“Have you accessed any medical interventions to
affirm your gender (for example, hormones,
surgeries to transition)?”

Hormones
(estrogen or
testosterone)

Living Full-Time in
Preferred Gender
Identity
Legally Affirmed
Gender

“Do you live full-time in your identified gender?”

Yes

“Have you legally affirmed your gender (i.e., name
change, gender marker change on documents)?”

Yes

“In the past 6 months, have you had any problems
getting health or medical services because of your
gender identity or gender presentation?”

Yes

“When you have received HIV prevention services
or programs, how specific were they to your needs
as a transgender or gender nonconforming
person?”

Very specific to
transgender and
gender
nonconforming
people; or Mostly
specific to
transgender and
gender
nonconforming
people

“Please indicate the extent to which you agree or
disagree with this statement: The provider where I
most often receive health care services is
knowledgeable about transgender and gender
nonconforming health.”

Strongly agree;
somewhat agree;
or neutral

Gender Identity
Prevented Healthcare
Access in Past 6
Months
Transgender-Focused
HIV Prevention
Experience

Provider
Knowledgeable
About Transgender
Health
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Family Supportive of
Gender Identity

“In general, how supportive is your family of your
gender identity?”

Very supportive;
or somewhat
supportive

HIV Prevention
Service
Participation

“In the past 6 months, have you accessed HIV
prevention services or programs (for example, risk
reduction counseling, demonstrations on how to
properly use condoms, programs for couples or
groups focused on reducing the risk of acquiring
HIV by changed behaviors)?”

Yes

HIV- or Gender
Identity-Focused
Program
Participation

“Other than this study, ATN 130, have you ever
participated in any programs, interventions,
research studies, support groups or individual
counseling sessions about HIV, sexual risk,
relationships, gender identity, gender expression,
or sexuality?”

Yes
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APPENDIX 2. Coding of Demographics and Confounders from ATN 130 Dataset
Demographic or
Confounder
Age
Gender Identity

Survey Question

Positive
Response(s)

“How old are you?”

Fill-in-the-blank
before “years”

“What is your current gender identity?”

Transgender Female

“

“Trans
female/Trans
woman”; or
“Female” if also
answers “Male”
to sex assigned
at birth

Transgender Male

“

“Trans
male/Trans
man”; or “Male”
if also answers
“Female” to sex
assigned at birth

Non-binary

“

“Genderqueer/
Gender nonconforming"; or
“A gender not
listed here”

“What sex were you assigned at birth, meaning
what the doctor put on your original birth
certificate?”

“Male”

“Are you of Hispanic (Spanish) or Latino
heritage?”

“Yes”

AMAB

Ethnicity
Hispanic/Latino
Race

“In addition to knowing whether or not you are of
Hispanic/Latino ethnic heritage, what is your racial
background?”

White

“

“White”

African American or
Black

“

“Black/African
American”
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Native American or
Alaska Native

“

“Native
American/
Alaskan Native”

Asian or Pacific
Islander

“

“Asian/Pacific
Islander”

Other

“

“Mixed”; or
“Other”

Education

“What is the highest level of education or grade
you have completed?”
“

Less than High
School Diploma

“None, no
formal
schooling”;
“Eighth grade or
less”; or
“More than
eighth grade but
did not complete
High School”

High School
Diploma or GED

“

“High School
Graduate”; or
“GED”

College

“

“Some
college/technical
education”;
“Technical
School
Graduate”;
“College
Graduate”;
“Some graduate
school”; or
“Master’s degree
or above”

Depression

GAD-7 Screening

Score of 10+

Anxiety

PHQ-2 Screening

Score of 3+

“I feel that I’m a person of worth, at least on an
equal plane with others.”

“Definitely
agree”; or
“Mostly agree”

Mental Health

High Self-Esteem
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Suicidal Ideation

“In your lifetime did you ever seriously consider
attempting suicide, that is taking some action to
end your own life?”

“Yes”

Attempted Suicide

“In your lifetime, did you attempt suicide, that is
try to kill yourself?”

“Yes”

Physical or Sexual
Abuse Ever

“Have you ever been slapped, punched, kicked,
beaten up, or otherwise physically or sexually hurt
by a boyfriend/girlfriend, spouse, or some other
intimate partner?”

“Yes”

Physical or Sexual
Abuse Under Age of
15
Socioeconomic

“Were you ever physically or sexually abused as a
child under age 15 years-old?”

“Yes”

Health Insurance

“What kind of insurance do you currently use to
pay for healthcare? (Check all that apply)”

Any answer
except “No
insurance”

Cost Prevented
Healthcare Access in
Past 6 Months

“Was there a time in the past 6 months when you
needed to see a doctor, but could not because of
cost?”

“Yes”

“Where do you most often receive your health care
services?”

Any answer
except “Don't
have regular
source of
healthcare”; or
“Don't seek
healthcare”

“Have you ever been a ward of the court/state
(DCFS, foster system, court-appointed group
home, etc.)?”

“Yes”

Homelessness

“Have you ever been homeless in your lifetime?”

“Yes”

Government
Assistance

“Have you or your family ever received assistance
from the Aid to Families with Dependent Children
(AFDC), Temporary Assistance for Needy
Families (TANF), food stamp, or free lunch
programs?”

“Yes”

Incarceration

“Have you ever been incarcerated (been put in jail
or prison, or held overnight after an arrest) or put in
juvenile detention (juvy)?”

“Yes”

Regular Healthcare
Site

Foster Care

HIV Risk Factors
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“People define sex work in many different ways.
For the following questions when we say sex work,
we mean trading sexual activity or favors for food,
money, a place to sleep, drugs or other goods.
Have you ever traded sexual activity or favors for
food, money, a place to sleep, drugs or other
material goods?”

“Yes”

Injection Drug Use

“Have you injected drugs to get high (IDU) in the
last 6 months? (This does not include testosterone
injections or hormone injections)”

“Yes”

STI Screening
History

“Have you EVER been screened by a doctor or
other provider for a Sexually Transmitted Infection
(STI), other than HIV? STIs include things such as
Chlamydia, trichomoniasis (trich), syphilis,
gonorrhea (clap), genital herpes, or genital warts
(HPV).”

“Yes”

STI History

“Have you EVER been told by a doctor or other
provider that you had a Sexually Transmitted
Infection (STI), other than HIV? STIs include
things such as chlamydia, trichomoniasis (trich),
syphilis, gonorrhea (clap), genital herpes, or genital
warts (HPV), other than HIV?”

“Yes”

Sex with Male in
Past 6 Months

“During the past 6 months, have you had oral, anal,
or vaginal sexual contact with a male partner(s)?
By male partners, we mean partners who were
assigned a male sex at birth and who identify as
male. This does not include transgender partners.”

“Yes”

Sex with Female in
Past 6 Months

“During the past 6 months, have you had oral, anal,
or vaginal sexual contact with a female partner(s)?
By female partners, we mean partners who were
assigned a female sex at birth and who identify as
female. This does not include transgender
partners.”

“Yes”

Sex with
Transgender in Past 6
Months

“During the past 6 months, have you had oral, anal,
or vaginal sexual contact with a transgender
partner(s)? By transgender partners, we mean
partners who were assigned a sex at birth that is

“Yes”

Sex Work

different from their current gender identity.”
Anal Sex in Past 6
Months

48 separate survey questions asking the frequency
of different behaviors involving anal sex in the past
6 months

37

Filling in 1 or
more as the
response to any

of these
questions
Condomless Sex in
Past 6 Months

82 separate survey questions asking the frequency
of different behaviors involving sex without a
condom in the past 6 months

Filling in 1 or
more as the
response to any
of these
questions

Condomless Anal
Sex in Past 6 Months

24 separate survey questions asking the frequency
of different behaviors involving anal sex without a
condom in the past 6 months

Filling in 1 or
more as the
response to any
of these
questions

Frequency of Anal
Sex in Past 6 Months

48 separate survey questions asking the frequency
of different behaviors involving anal sex in the past
6 months

Sum of fill-inthe-blank
responses to
each question

Frequency of
Condomless Sex in
Past 6 Months

82 separate survey questions asking the frequency
of different behaviors involving sex without a
condom in the past 6 months

Sum of fill-inthe-blank
responses to
each question

Frequency of
Condomless Anal
Sex in Past 6 Months

24 separate survey questions asking the frequency
of different behaviors involving anal sex without a
condom in the past 6 months

Sum of fill-inthe-blank
responses to
each question
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